211 related articles for article (PubMed ID: 23300522)
41. Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures.
Madsen JJ; Ye L; Frimurer TM; Olsen OH
Protein Sci; 2022 Nov; 31(11):e4456. PubMed ID: 36134696
[TBL] [Abstract][Full Text] [Related]
42. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists.
Swaminath G; Deupi X; Lee TW; Zhu W; Thian FS; Kobilka TS; Kobilka B
J Biol Chem; 2005 Jun; 280(23):22165-71. PubMed ID: 15817484
[TBL] [Abstract][Full Text] [Related]
43. Salmeterol's extreme β2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Baker JG; Proudman RG; Hill SJ
Mol Pharmacol; 2015 Jan; 87(1):103-20. PubMed ID: 25324048
[TBL] [Abstract][Full Text] [Related]
44. The role of conformational ensembles of seven transmembrane receptors in functional selectivity.
Vaidehi N; Kenakin T
Curr Opin Pharmacol; 2010 Dec; 10(6):775-81. PubMed ID: 20933468
[TBL] [Abstract][Full Text] [Related]
45. Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening?
Tang H; Wang XS; Hsieh JH; Tropsha A
Proteins; 2012 Jun; 80(6):1503-21. PubMed ID: 22275072
[TBL] [Abstract][Full Text] [Related]
46. Mechanism of intracellular allosteric β
Liu X; Ahn S; Kahsai AW; Meng KC; Latorraca NR; Pani B; Venkatakrishnan AJ; Masoudi A; Weis WI; Dror RO; Chen X; Lefkowitz RJ; Kobilka BK
Nature; 2017 Aug; 548(7668):480-484. PubMed ID: 28813418
[TBL] [Abstract][Full Text] [Related]
47. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
Slack RJ; Barrett VJ; Morrison VS; Sturton RG; Emmons AJ; Ford AJ; Knowles RG
J Pharmacol Exp Ther; 2013 Jan; 344(1):218-30. PubMed ID: 23131596
[TBL] [Abstract][Full Text] [Related]
48. Differences between G-Protein-Stabilized Agonist-GPCR Complexes and their Nanobody-Stabilized Equivalents.
Saleh N; Ibrahim P; Clark T
Angew Chem Int Ed Engl; 2017 Jul; 56(31):9008-9012. PubMed ID: 28481446
[TBL] [Abstract][Full Text] [Related]
49. Activation mechanism of the β2-adrenergic receptor.
Dror RO; Arlow DH; Maragakis P; Mildorf TJ; Pan AC; Xu H; Borhani DW; Shaw DE
Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18684-9. PubMed ID: 22031696
[TBL] [Abstract][Full Text] [Related]
50. Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
Soriano-Ursúa MA; McNaught-Flores DA; Nieto-Alamilla G; Segura-Cabrera A; Correa-Basurto J; Arias-Montaño JA; Trujillo-Ferrara JG
Bioorg Med Chem; 2012 Jan; 20(2):933-41. PubMed ID: 22182578
[TBL] [Abstract][Full Text] [Related]
51. Detection of G protein-selective G protein-coupled receptor (GPCR) conformations in live cells.
Malik RU; Ritt M; DeVree BT; Neubig RR; Sunahara RK; Sivaramakrishnan S
J Biol Chem; 2013 Jun; 288(24):17167-78. PubMed ID: 23629648
[TBL] [Abstract][Full Text] [Related]
52. β₂-adrenergic receptor activation by agonists studied with ¹⁹F NMR spectroscopy.
Horst R; Liu JJ; Stevens RC; Wüthrich K
Angew Chem Int Ed Engl; 2013 Oct; 52(41):10762-5. PubMed ID: 23956158
[No Abstract] [Full Text] [Related]
53. Cell-based assays and molecular dynamics analysis of a boron-containing agonist with different profiles of binding to human and guinea pig beta2 adrenoceptors.
Soriano-Ursúa MA; Bello M; Hernández-Martínez CF; Santillán-Torres I; Guerrero-Ramírez R; Correa-Basurto J; Arias-Montaño JA; Trujillo-Ferrara JG
Eur Biophys J; 2019 Jan; 48(1):83-97. PubMed ID: 30386878
[TBL] [Abstract][Full Text] [Related]
54. Conformational and Thermodynamic Landscape of GPCR Activation from Theory and Computation.
Dong SS; Goddard WA; Abrol R
Biophys J; 2016 Jun; 110(12):2618-2629. PubMed ID: 27332120
[TBL] [Abstract][Full Text] [Related]
55. Insight into partial agonism by observing multiple equilibria for ligand-bound and G
Solt AS; Bostock MJ; Shrestha B; Kumar P; Warne T; Tate CG; Nietlispach D
Nat Commun; 2017 Nov; 8(1):1795. PubMed ID: 29176642
[TBL] [Abstract][Full Text] [Related]
56. Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors.
Lakkaraju SK; Yu W; Raman EP; Hershfeld AV; Fang L; Deshpande DA; MacKerell AD
J Chem Inf Model; 2015 Mar; 55(3):700-8. PubMed ID: 25692383
[TBL] [Abstract][Full Text] [Related]
57. Structural insights into binding specificity, efficacy and bias of a β
Masureel M; Zou Y; Picard LP; van der Westhuizen E; Mahoney JP; Rodrigues JPGLM; Mildorf TJ; Dror RO; Shaw DE; Bouvier M; Pardon E; Steyaert J; Sunahara RK; Weis WI; Zhang C; Kobilka BK
Nat Chem Biol; 2018 Nov; 14(11):1059-1066. PubMed ID: 30327561
[TBL] [Abstract][Full Text] [Related]
58. Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor.
Weiss DR; Ahn S; Sassano MF; Kleist A; Zhu X; Strachan R; Roth BL; Lefkowitz RJ; Shoichet BK
ACS Chem Biol; 2013 May; 8(5):1018-26. PubMed ID: 23485065
[TBL] [Abstract][Full Text] [Related]
59. GPCR agonist binding revealed by modeling and crystallography.
Katritch V; Abagyan R
Trends Pharmacol Sci; 2011 Nov; 32(11):637-43. PubMed ID: 21903279
[TBL] [Abstract][Full Text] [Related]
60. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s).
Green SA; Rathz DA; Schuster AJ; Liggett SB
Eur J Pharmacol; 2001 Jun; 421(3):141-7. PubMed ID: 11516429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
